Matthew Siegel

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/12048063/publications.pdf

Version: 2024-02-01

567281 940533 1,674 17 15 16 citations h-index g-index papers 17 17 17 1602 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Inhibition of sodium/hydrogen exchanger 3 in the gastrointestinal tract by tenapanor reduces paracellular phosphate permeability. Science Translational Medicine, 2018, 10, .	12.4	91
2	Development and Characterization of a Human and Mouse Intestinal Epithelial Cell Monolayer Platform. Stem Cell Reports, 2017, 9, 1976-1990.	4.8	122
3	Safety, Tolerability, and Activity of ALV003: Results from Two Phase 1 Single, Escalating-Dose Clinical Trials. Digestive Diseases and Sciences, 2012, 57, 440-450.	2.3	88
4	The effects of ALV003 pre-digestion of gluten on immune response and symptoms in celiac disease in vivo. Clinical Immunology, 2010, 134, 289-295.	3.2	125
5	Interferon-Î ³ Released by Gluten-Stimulated Celiac Disease-Specific Intestinal T Cells Enhances the Transepithelial Flux of Gluten Peptides. Journal of Pharmacology and Experimental Therapeutics, 2009, 329, 657-668.	2.5	37
6	Tissue transgluaminase 2 expression in meningiomas. Journal of Neuro-Oncology, 2008, 90, 125-132.	2.9	19
7	Extracellular Transglutaminase 2 Is Catalytically Inactive, but Is Transiently Activated upon Tissue Injury. PLoS ONE, 2008, 3, e1861.	2.5	174
8	Transglutaminase 2 Regulates Mallory Body Inclusion Formation and Injury-Associated Liver Enlargement. Gastroenterology, 2007, 132, 1515-1526.	1.3	66
9	Combination Enzyme Therapy for Gastric Digestion of Dietary Gluten in Patients With Celiac Sprue. Gastroenterology, 2007, 133, 472-480.	1.3	205
10	Structure-based design of $\hat{l}\pm$ -amido aldehyde containing gluten peptide analogues as modulators of HLA-DQ2 and transglutaminase 2. Bioorganic and Medicinal Chemistry, 2007, 15, 6253-6261.	3.0	41
11	Cyclic and dimeric gluten peptide analogues inhibiting DQ2-mediated antigen presentation in celiac disease. Bioorganic and Medicinal Chemistry, 2007, 15, 6565-6573.	3.0	85
12	Transglutaminase 2 inhibitors and their therapeutic role in disease states., 2007, 115, 232-245.		170
13	Inhibition of HLA-DQ2-Mediated Antigen Presentation by Analogues of a High Affinity 33-Residue Peptide from α2-Gliadin. Journal of the American Chemical Society, 2006, 128, 1859-1867.	13.7	73
14	Pharmacologic transglutaminase inhibition attenuates drug-primed liver hypertrophy but not Mallory body formation. FEBS Letters, 2006, 580, 2351-2357.	2.8	14
15	Rational Design of Combination Enzyme Therapy for Celiac Sprue. Chemistry and Biology, 2006, 13, 649-658.	6.0	117
16	Chemistry and Biology of Dihydroisoxazole Derivatives: Selective Inhibitors of Human Transglutaminase 2. Chemistry and Biology, 2005, 12, 469-475.	6.0	154
17	Effect of Pretreatment of Food Gluten With Prolyl Endopeptidase on Gluten-Induced Malabsorption in Celiac Sprue. Clinical Gastroenterology and Hepatology, 2005, 3, 687-694.	4.4	93